mulpleo (previously lusutrombopag shionogi)
shionogi b.v. - lusutrombopag - trombocitopēnija - antihemorāģija - mulpleo ir indicēts, lai ārstētu smaga trombocitopēnija pieaugušiem pacientiem ar hronisku aknu slimību pārcieš invazīvās procedūras,.
dicynone 250 mg tabletes
sandoz d.d., slovenia - etamsilāts - tablete - 250 mg
dicynone 250 mg/2 ml šķīdums injekcijām
sandoz d.d., slovenia - etamsilāts - Šķīdums injekcijām - 250 mg/2 ml
doptelet
swedish orphan biovitrum ab (publ) - avatrombopag maleate - trombocitopēnija - antihemorāģija - doptelet ir indicēts, lai ārstētu smaga trombocitopēnija pieaugušiem pacientiem ar hronisku aknu slimību, kas ir plānots veikt invazīvo procedūru. doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. kortikosteroīdi, imūnglobulīni).
tavlesse
instituto grifols s.a. - fostamatinib dinātrija - trombocitopēnija - citi hemostatiskie līdzekļi sistēmiskai lietošanai - tavlesse ir indicēts, lai ārstētu hronisku trombocitopēnija imūnās (ipp) pieaugušiem pacientiem, kam ir grūti kūstoši uz citām zālēm.
nplate
amgen europe b.v. - romiplostim - purpura, trombocitopēnija, idiopātija - antihemorāģija - adults:nplate is indicated for the treatment of primary immune thrombocytopenia (itp) in adult patients who are refractory to other treatments (e. kortikosteroīdi, imūnglobulīni). paediatrics:nplate is indicated for the treatment of chronic primary immune thrombocytopenia (itp) in paediatric patients one year of age and older who are refractory to other treatments (e. kortikosteroīdi, imūnglobulīni).
revolade
novartis europharm limited - eltrombopags - purpura, trombocitopēnija, idiopātija - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 un 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 un 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.
hemlibra
roche registration limited - emicizumabs - a hemofīlija - antihemorāģija - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra var izmantot visās vecuma grupās.
eltrombopag olainfarm 12,5 mg apvalkotās tabletes
olainfarm, as, latvia - eltrombopags - apvalkotā tablete - 12,5 mg
eltrombopag olainfarm 25 mg apvalkotās tabletes
olainfarm, as, latvia - eltrombopags - apvalkotā tablete - 25 mg